The Multiple Myeloma Channel on VJHemOnc is an independent medical education platform, supported with funding from BMS (Gold) and Legend Biotech (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
ASH 2022 | Using drug class refractoriness to classify patients with R/R myeloma receiving modern therapy
Luciano Costa, MD, PhD, UAB School of Medicine, Birmingham, AL, discusses using drug class refractoriness, rather than number of prior lines of therapy (LOT), to classify patients with multiple myeloma (MM) undergoing therapy. It was found that in patients receiving modern therapy for relapsed/refractory (R/R) myeloma, drug class refractoriness predicted overall response rate (ORR) and progression-free survival (PFS) more accurately, and Dr Costa explains the importance of using these findings when selecting patients for clinical trials and treatment with novel agents. This interview took place at the 64th ASH Annual Meeting and Exposition congress in New Orleans, LA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Disclosures
Sanofi: Consultancy, Honoraria; Adaptive Biotechnologies: Consultancy, Honoraria; Bristol Myers Squibb: Consultancy, Honoraria, Research Funding; Genentech: Research Funding; AbbVie: Research Funding; Amgen: Consultancy, Honoraria, Research Funding; Janssen: Consultancy, Honoraria, Research Funding.
